News Search Results
Jun 19, 2025, 07:30 ET Saol Therapeutics Announces Poster Presentation at the UMDF Mitochondrial Medicine 2025 Conference
GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Jun 18, 2025, 11:00 ET Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®
Reports: Global CNS Specific Antisense Oligonucleotides Market Size By Indication (Hereditary Transthyretin Amyloidosis (hATTR), Huntington's
More news about: Verified Market Research
Jun 18, 2025, 03:30 ET Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy
layer pathology reflects and can predict disease activity and disability progression in MS. By establishing the retina as a surrogate marker of broader CNS neurodegeneration, his research has paved the way for novel approaches to assess neuroprotection and neuro-restoration in clinical trials. Prof. Saidha
More news about: Rewind Therapeutics
Jun 16, 2025, 16:00 ET Cohen & Steers Appoints Seth Laughlin as Head of Real Estate Strategy & Research
YORK, June 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Seth Laughlin as Senior Vice President and Head of Real Estate Strategy & Research.
More news about: Cohen & Steers, Inc.
Jun 16, 2025, 16:00 ET Med-Fine Capital Closes New USD Fund, Advancing China Biotech's Global Innovation and Expansion
Vince Deng, Partner and Head of Biotech Investment at Med-Fine Capital. "Our focus areas include oncology, autoimmune, metabolic and CNS diseases, where we invest in globally competitive and differentiated innovation. We actively support promising Chinese biotech companies to go global,
More news about: Med-Fine Capital
Jun 16, 2025, 11:25 ET Regenerative Medicine Market to Hit USD 115.6 Billion by 2029 | Rising Demand in Dermatology & Orthopedic Fuels 19.2% CAGR | Valuates Reports
/PRNewswire/ -- Regenerative Medicine Market is Segmented by Type (Cell Therapy, Tissue Engineering, Biomaterial), by Application (Dermatology, Cardiovascular, CNS, Orthopedic).
More news about: Valuates Reports
Jun 16, 2025, 09:00 ET Cohen & Steers Invests $300 Million On Behalf of Clients with Hudson Pacific Properties to Support Balance Sheet Recapitalization
Cohen & Steers, Inc. (NYSE: CNS), announced today that the firm, on behalf of its clients' accounts, has invested $300 million in Hudson Pacific Properties,
More news about: Cohen & Steers, Inc.
Jun 16, 2025, 07:00 ET NLS Pharmaceutics CEO Issues Letter to Shareholders
Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.
More news about: NLS Pharmaceutics Ltd.
Jun 13, 2025, 11:00 ET Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
effector cell-associated neurotoxicity syndrome (ICANS), one Grade 1 and one Grade 3. The Grade 3 event occurred in a patient with central nervous system (CNS) lymphoma. Overall, 84 percent of patients (n=21) had Grade 3/4 treatment-emergent adverse events (TEAEs), and 28 percent (n=7) reported serious TEAEs.
More news about: Johnson & Johnson
Jun 12, 2025, 12:01 ET Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance
More news about: Specialised Therapeutics
Jun 12, 2025, 07:00 ET Corero Network Security and Rocket Fibre Sign Multi-Year Deal to Secure Growth and Launch Real-Time DDoS Protection Services
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a multi-year agreement with
More news about: Corero Network Security
Jun 12, 2025, 06:13 ET Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.
More news about: Dizal Pharmaceutical
Jun 11, 2025, 17:31 ET Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight
barrier, targeting both B cells and microglia to mitigate smoldering neuroinflammation in multiple sclerosis (MS). By focusing on central nervous system (CNS) processes that drive neurodegeneration, it aims to address disease progression beyond peripheral inflammation. In March 2025,
More news about: DelveInsight Business Research, LLP
Jun 11, 2025, 12:30 ET World Precision Instruments and SynVivo Launch Next-Generation Multiplexed TEER-on-a-Chip Platform for Real-Time Organ-on-a-Chip Cell Monitoring
technology with WPI's industry-leading TEER measurement expertise, we're delivering a powerful solution for researchers tackling complex questions in CNS drug development, inflammation, and drug discovery." WPI's EVOM™ family of TEER instrumentation has set the standard for barrier function assessment
More news about: SynVivo and World Precision Instruments
Jun 11, 2025, 10:25 ET Alamar Biosciences, Alzheimer's Disease Data Initiative a Gates Ventures uzavírají globální partnerství pro pokrok v translačním výzkumu Alzheimerovy choroby.
NULISAseq™ CNS Disease Panel 120 a
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:22 ET Alamar Biosciences, die Alzheimer's Disease Data Initiative und Gates Ventures schließen sich zu einer globalen Partnerschaft zusammen, um die translationale Forschung auf dem Gebiet der Alzheimer-Krankheit voranzutreiben.
NULISAseq™ CNS Disease Panel 120 und das
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:17 ET Alamar Biosciences, Инициатива по сбору данных о болезни Альцгеймера и Gates Ventures объединяются в глобальном партнерстве для продвижения трансляционных исследований болезни Альцгеймера.
NULISAseq™ CNS Disease Panel 120 и
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:13 ET Spoločnosti Alamar Biosciences, Iniciatíva na získavanie údajov o Alzheimerovej chorobe a Gates Ventures sa spájajú v globálnom partnerstve s cieľom posunúť vpred translačný výskum Alzheimerovej choroby.
biomarkeroch." V rámci tejto iniciatívy budú vo výskumných centrách v Spojených štátoch, Švédsku, Spojenom kráľovstve a Indii implementované panely ochorení CNS
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:09 ET Alamar Biosciences, Alzheimer's Disease Data Initiative, dan Gates Ventures Bersatu dalam Kemitraan Global untuk Memajukan Penelitian Translasi Tentang Penyakit Alzheimer.
NULISAseq™ CNS Disease Panel 120 dan
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:06 ET Alamar Biosciences、Alzheimer's Disease Data Initiative、Gates Venturesが連携し、アルツハイマー病のトランスレーショナルリサーチを推進する国際的パートナーシップを締結
NULISAseq™ CNS Disease Panel 120および
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:02 ET Alamar Biosciences, Alzheimer's Disease Data Initiative i Gates Ventures jednoczą się w ramach międzynarodowej współpracy na rzecz rozwoju badań translacyjnych nad chorobą Alzheimera
NULISAseq™ CNS Disease Panel 120 oraz
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 09:30 ET "STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
/PRNewswire/ -- The represented biotech companies primarily focus on therapeutics development across oncology, respiratory diseases, rare diseases, and CNS disorders, alongside advanced drug discovery technologies including 3D microtissues, transcriptomics, and novel delivery systems.
More news about: Swiss Business Hub USA
Jun 11, 2025, 08:00 ET Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Jun 11, 2025, 03:32 ET 알라마르 바이오사이언시즈 •알츠하이머병 데이터 이니셔티브•게이츠 벤처스, 알츠하이머병의 중개연구 진전시키기 위한 글로벌 파트너십 체결
NULISAseq™ CNS 질환 패널 120(NULISAseq™ CNS Disease Panel 120) 및
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 01:38 ET Alamar Biosciences、Alzheimer's Disease Data Initiative 與 Gates Ventures 建立全球合作夥伴關係，推進阿茲海默症的轉化研究。
NULISAseq™ CNS 疾病專家小組 120 和
More news about: Alamar Biosciences, Inc.